Compound for inhibiting HBV transcription and hepatitis B surface antigen and application thereof
By developing compounds 1-4, using its inhibitory HBV transcription mechanism to target hepatitis B surface antigen, the problem of poor targeting of HBsAg in the prior art was solved, significant antiviral effects were achieved, and new for functional hepatitis B cure Drug pathway.
Patent Information
- Application Number
- CN202411174700.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-12-03
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of pharmaceutical chemistry, and in particular to a compound for inhibiting HBV transcription and hepatitis B surface antigen and application thereof. Background Art
[0002] Hepatitis B (HBV) is a global epidemic caused by the hepatitis B virus (HBV). Uncontrolled chronic HBV infection can develop into life-threatening end-stage chronic liver diseases such as cirrhosis and hepatocellular carcinoma, resulting in nearly 880,000 deaths each year.
[0003] HBV is a DNA enveloped virus belonging to the family Hepadnaviridae. HBV virus particles are composed of nucleocapsid and envelope proteins. The HBV genome is a 3.2kb relaxed circular DNA (rcDNA), of which the longer strand is designated as the negative strand (-) and the shorter strand is the positive strand (+). The negative strand is the coding strand, which contains four overlapping open reading frames (ORFs) (preC / C, P, preS / S and X), four promoters (core promoter, PreS1 promoter, PreS2 / S promoter and X promoter) and two enhancers (EnhⅠ and EnhⅡ), which can transcribe four types of RNA (3.5kbPreC / C mRNA, 2.4kbPreS1mRNA, 2.1kbPreS2 / S mRNA and 0.7kbX mRNA). PreC / CORF is responsible for encoding HBeAg and HBcAg; PORF encodes HBV DNA polymerase; PreS / S ORF encodes large (L), medium (M) and small (S) envelope proteins; XORF encodes X protein (HBx). The envelope protein of HBV virus particles binds to the sodium taurocholate cotransporting polypeptide (NTCP) receptor and enters the cell. After the nucleocapsid enters the cell, rcDNA is released for transcription, replication and translation. After HBV infects cells, a variety of virus particles are produced, such as Dane particles, HBV RNA viruses, "empty" viruses, naked capsids, subviral particles, etc. The number of these different virus particles varies greatly. For example, the amount of Dane particles produced is 1-100 times more than that of HBV RNA viruses, 100-144 times less than that of "empty" viruses, and 10,000-100,000 times less than that of subviral particles. In chronic infection, the difficulty of the human body to clear HBV may be caused by the secretion of extremely excessive subviral particles (Subviralparticle, SVP, also known as HBs particles). SVP is considered to be a decoy of the immune system that can exhaust B and T cell responses, thereby contributing to persistent viral infection. Clinically, the disappearance of HBsAg or the appearance of anti-HBs antibodies marks a lasting immune control or functional cure of HBV infection. Therefore, it is of great significance to develop antiviral drugs targeting HBsAg to achieve this therapeutic goal.
[0004] Currently, the clinically approved drugs for hepatitis B are mainly pegylated interferon α (Peg-IFNα) and nucleoside analogs (NUCs). Peg-IFNα is an immunomodulator that inhibits the synthesis of HBV DNA by stimulating the production of antiviral enzymes; NUCs reduce the production of HBV viral particles by directly inhibiting the reverse transcription activity of HBV DNA polymerase. Neither of them can target HBsAg to achieve functional cure. Therefore, there is an urgent need to research and develop new drugs targeting HBsAg to achieve the goal of functional cure of hepatitis B.
[0005] There are some studies on therapeutic strategies to achieve functional cure by targeting HBsAg. A variety of candidate molecules targeting HBsAg have been studied and developed, including natural products, small molecule compounds, RNA interference (siRNA), antisense oligonucleotides (ASO), nucleic acid polymers (NAPs) and immunosuppressants. However, these methods and drugs still have shortcomings such as short half-life, high drug toxicity, poor targeting, or unclear mechanism of action, so it is still necessary to study and develop new compounds. Summary of the invention
[0006] The purpose of the present invention is to provide a compound for inhibiting HBV transcription and hepatitis B surface antigen and its application in view of the above problems.
[0007] In order to achieve its purpose, the present invention adopts the following technical solution:
[0008] The first aspect of the present invention provides the use of a compound or a pharmaceutically acceptable salt thereof in any of the following:
[0009] (1) Application in the preparation of reagents for inhibiting HBV transcription;
[0010] (2) Application in the preparation of HBV inhibitors;
[0011] (3) Application in the preparation of hepatitis B surface antigen inhibitors;
[0012] (4) Use in the preparation of drugs for treating hepatitis B virus infectious diseases or symptoms;
[0013] (5) Application in the preparation of drugs against hepatitis B virus;
[0014] The compound is selected from any one of the following compounds:
[0015]
[0016]
[0017] Preferably, the compound is a compound having a chemical structural formula as shown in Formula (1-4).
[0018] Preferably, the drug further comprises a pharmaceutically acceptable carrier.
[0019] The second aspect of the present invention provides a product for inhibiting HBV transcription or inhibiting HBV or inhibiting hepatitis B surface antigen, containing at least one of the compounds represented by the above-mentioned formula I, formula (1-1), formula (1-2), formula (1-4), and formula (1-6) as an active ingredient, or containing a pharmaceutically acceptable salt of the compound.
[0020] Preferably, the product is a medicine, and the medicine further contains a pharmaceutically acceptable carrier.
[0021] The third aspect of the present invention provides a pharmaceutical composition for treating hepatitis B virus infectious diseases or diseases or for anti-hepatitis B virus, comprising as an active ingredient at least one of the compounds represented by the above-mentioned formula I, formula (1-1), formula (1-2), formula (1-4), and formula (1-6) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0022] The active ingredient of the above-mentioned pharmaceutical composition exerts its efficacy by inhibiting hepatitis B surface antigen.
[0023] Preferably, in the above-mentioned pharmaceutical composition, the compound is a compound having a chemical structural formula represented by formula (1-4), which inhibits hepatitis B surface antigen by inhibiting HBV transcription.
[0024] The compound with the chemical structure shown in formula (1-4) affects the hepatitis B surface antigen by affecting the production of HBV RNA.
[0025] Preferably, the product dosage form of the pharmaceutical composition is capsule, tablet, pill, granule, oral solution preparation, microcapsule preparation or injection.
[0026] The beneficial effects of the present invention are:
[0027] This study used the cell model constructed by the team in the early stage to screen a small molecule compound that inhibits HBsAg from 5088 compounds, and screened out compounds with better effects by screening the structural analogs of the compound. The antiviral effects of these compounds were then evaluated in different cell models. The present invention found a compound that significantly inhibits HBsAg, compound 1-4, and studied its mechanism of action. It was found that compound 1-4 is a new potential antiviral drug that inhibits HBsAg by inhibiting HBV transcription. Compound 1-4 affects HBsAg by affecting the production of HBV RNA. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 This is the result of the inhibitory effect of compound 35C7 on hepatitis B surface antigen.
[0029] Figure 2 This is the result of screening analogs of compound 35C7 that inhibit HBsAg.
[0030] Figure 3 These are the evaluation results of the antiviral effects of compounds 1-4 in a stable transfection model.
[0031] Figure 4These are the evaluation results of the antiviral effects of compounds 1-4 on the AML12 cell model.
[0032] Figure 5 These are the results of the effects of compounds 1-4 on HBV RNA (AB) and the degradation rate of HBV RNA (C), as well as the effects on HBsAg secretion in a cell model (DF). DETAILED DESCRIPTION
[0033] The present invention will be further described below in conjunction with embodiments, but the present invention is not limited thereto.
[0034] The experimental methods in the following examples are conventional methods unless otherwise specified.
[0035] Sources of reagents and materials used in the examples of this application:
[0036] Compound library: purchased from Shanghai Taoshu Biotechnology Co., Ltd. (China);
[0037] DMEM medium, fetal bovine serum (FBS), and PBS buffer: Hyclone, USA;
[0038] Southern blot, Northern blot detection kit, reverse transcription kit, qPCR kit: Roche, Germany;
[0039] HBV surface antigen: Shanghai Kehua Bioengineering Co., Ltd., China;
[0040] HepG2 cells: American Type Culture Collection;
[0041] HepG2-PB-S-HiBiT cell line: Screening drugs targeting HBsAg requires a simple and reliable cell screening system. This research team has successfully constructed a simple and effective HBsAg characterization model, S-HiBiT, and then constructed a stable expression cell line HepG2-PB-S-HiBiT, and successfully verified that the stable expression cell line can be used for drug screening (see Chinese patent application 202311448773.1, invention name: Compounds that inhibit hepatitis B surface antigen and their applications, publication number CN117503772A). The HepG2-PB-S-HiBiT cells were also used in this application study.
[0042] Plasmid S-HiBiT: the same as plasmid S-HiBiT in CN 117503772A. HiBiT is a luciferase tag.
[0043] Example 1: Screening of compounds targeting hepatitis B surface antigen
[0044] 1. Preliminary screening of compounds targeting hepatitis B surface antigen
[0045] The preserved HepG2-PB-S-HiBiT cells were revived and then used for compound screening. The screening process is as follows: HepG2-PB-S-HiBiT cells were revived and cultured in a 10 cm culture dish with DMEM medium containing 10% fetal bovine serum. When the cell growth state is good, the cells are digested and inoculated into 96-well plates. The day after cell inoculation, the compounds to be tested were added to the 96-well plates at a final concentration of 10 μM, and 2 replicates were made for each compound. The HiBiT level in the supernatant was detected 72 hours after drug addition. We first screened 5088 small molecule compounds in the compound library purchased from Taoshu Company and found that 591 of them could reduce the HiBiT level by 2 times or more. Then, the experiment was repeated for these 591 compounds, and 126 of them could reduce the HiBiT level by 2 times or more again.
[0046] Then the 126 compounds were further screened, and the screening process was as follows: HepG2.2.15 cells were revived and cultured in a 10 cm culture dish with DMEM medium containing 10% fetal bovine serum. When the cell growth state was better, the cells were digested and inoculated into a 48-well plate. On the second day after cell inoculation, the compounds to be tested were added to the 48-well plate at a final concentration of 10 μM, and 2 replicates were made for each compound. The HBsAg level in the supernatant was detected 72 hours after the addition of the drug, and it was found that 40 compounds could reduce HBsAg by 2 times or more. Then the experiment was repeated on these 40 compounds, and 8 of them could reduce HBsAg by 2 times or more again. To further evaluate whether the eight candidate compounds inhibited HBsAg in a dose-dependent manner within the specified concentration range, the level of HBsAg in the supernatant was detected by ELISA. The results showed that among the eight candidate compounds, compound 35C7 (4-amino-5-(4-chlorobenzoyl)-N-[(4-chlorophenyl)methyl]-2-(2-methylanilino)thiophene-3-carboxamide) had a dose-dependent inhibitory effect on secreted HBsAg ( Figure 1 A, 1B, 1C). In summary, after multiple rounds of screening, compound 35C7 was found to inhibit secretory HBsAg and reduce it in a concentration gradient-dependent manner. The chemical structure of compound 35C7 is shown in Formula I:
[0047]
[0048] 2. Screening of analogs of compound 35C7
[0049] Subsequently, we explored six analogues of compound 35C7 (purchased from Taoshu Company) that were similar to the main groups of compound 35C7, namely compound 1-1 (4-amino-5-(4-bromobenzoyl)-2-[(3-chloro-4-methylphenyl)amino]thiophene-3-carboxamide), compound 1-2 (4-amino-5-benzoyl-N-[2-(cyclohex-1-en-1-yl)ethyl]-2-[(2,5-dimethoxyphenyl)amino]thiophene-3-carboxamide), compound 1-3 (4-amino-5-benzoyl-2-[( The inhibitory effects of compound 1-1, compound 1-2, compound 1-3, compound 1-4 (4-amino-5-benzoyl-2-[(3,4-dichlorophenyl)amino]-N-(4-ethoxyphenyl)thiophene-3-carboxamide), compound 1-5 (4-amino-2-(benzylamino)-5-(4-chlorobenzoyl)thiophene-3-carbonitrile), and compound 1-6 (4-amino-5-{[1,1'-biphenyl]-4-carbonyl}-2-(anilino)thiophene-3-carbonitrile) on HBsAg. The chemical structures of compounds 1-1, 1-2, 1-3, 1-4, 1-5, and 1-6 are shown in formula (1-1), formula (1-2), formula (1-3), formula (1-4), formula (1-5), and formula (1-6) respectively.
[0050]
[0051] The research process is as follows: HepG2 cells, HepG2.2.15 cells and HepAD38 cells were revived and cultured in 10 cm culture dishes with DMEM medium containing 10% fetal bovine serum. When the cell growth state is better, the cells are digested and inoculated into 48-well plates. On the second day after cell inoculation, different test compounds and negative controls (DMSO) were added to 48-well plates at a final concentration of 10 μM, and 2 replicates were made for each compound. 72 hours after drug addition, the HBsAg level in the supernatant was detected.
[0052] The results showed that in different cell lines, compound 1-1, compound 1-2, compound 1-4 (CAS No.: 702655-24-1), and compound 1-6 all had certain inhibitory effects, and compound 1-4 showed better HBsAg inhibition than other analogs ( Figure 2 A). To further evaluate the performance of compounds 1-4, different concentrations of compounds 1-4 were applied to HepG2.2.15 cells, and HBs levels and cell activity were detected after 3 days of treatment. The results showed that the IC50 of compounds 1-4 against HBsAg in HepG2.2.15 cells was 4.749 μM, and the CC50 was greater than 20 μM. The HBsAg inhibitory effect was clearly distinguished from the cytotoxic performance ( Figure 2 B).
[0053] In summary, compound 1-4 (molecular formula: C 26 H 21 Cl2N3O3S) has a certain effect on inhibiting HBsAg and has potential application value.
[0054] Example 2: Evaluation of the antiviral activity of compounds 1-4 in different cell models
[0055] 1. Evaluate the antiviral effects of compounds 1-4 in the HBV stable transfection model
[0056] Different concentrations of compounds 1-4 were applied to HepG2.2.15 cells, and the HBsAg level in the supernatant was detected after 72 hours. The results showed that compounds 1-4 reduced HBsAg in a dose-dependent manner ( Figure 3 A). The intracellular HBsAg level was detected by Western blot. Compounds 1-4 can reduce the intracellular HBsAg protein level in a dose-dependent manner ( Figure 3 B). Then, the levels of HBV RNA and DNA in cells were detected by Northern blot and Southern blot, and it was found that compounds 1-4 could reduce the levels of HBV RNA and DNA in cells ( Figure 3 C, 3D).
[0057] 2. Evaluation of the antiviral activity of compounds 1-4 on the mouse liver cell line AML12
[0058] α mouse liver 12 (AML12) cells are a type of hepatocytes derived from the liver of transgenic mice overexpressing transforming growth factor (TGF) α. They are a common and mature hepatocyte model. Plasmid S-HiBiT was transfected into AML12 cells, followed by treatment with different concentrations of compounds 1-4. Supernatant HBsAg levels and NLUC luciferase activity were detected after 72 hours. The results showed that compounds 1-4 were able to inhibit HBsAg and NLUC luciferase activity in AML12 cells in a dose-dependent manner ( Figure 4 A). Western blot analysis showed that compounds 1-4 could also reduce the intracellular HBsAg protein level in a dose-dependent manner ( Figure 4 B).
[0059] Example 3: Exploring the mechanism of reducing HBsAg by compounds 1-4
[0060] 1. Compounds 1-4 reduce HBsAg by affecting the production of HBV RNA
[0061] The above results of the antiviral effect of compound 1-4 on reducing HBsAg in the stable transfection model suggest that compound 1-4 can affect HBV RNA. Next, we used qRT-PCR to detect the effects of compound 1-4 on HBV total RNA and 3.5kb RNA in the stable transfection model HepG2.2.15 and HepAD38 cell model.
[0062] The primer sequences for qRT-PCR are as follows:
[0063] Primer name Primer sequences SEQ ID NO Total HBV RNAs forward primer 5'-ACCGACCTTGAGGCATACTT-3' SEQ ID NO.1 Total HBV RNAs reverse primer 5'-GCCTACAGCCTCCTAGTACA-3' SEQ ID NO.2 HBV3.5-kbmRNA forward primer 5'-GCCTTAGAGTCTCCTGAGCA-3' SEQ ID NO.3 HBV3.5-kbmRNA reverse primer 5'-GAGGGAGTTCTTCTTCTAGG-3' SEQ ID NO.4
[0064] The PCR amplification conditions were as follows: pre-denaturation at 95°C for 1 min; denaturation at 95°C for 20 s, annealing at 60°C for 20 s, and extension at 72°C for 30 s, for 40 cycles.
[0065] The results showed that compounds 1-4 could reduce both the HBV total RNA level and the HBV 3.5kb RNA level ( Figure 5 A, 5B). Subsequently, we detected the effect of compound 1-4 on the stability of HBV mRNA. Actinomycin D can inhibit transcription by specifically inhibiting RNA transcriptase II and is often used to study the stability of mRNA. Plasmid S-HiBiT was transfected into HepG2 cells, and actinomycin D was added after 48 hours of treatment with compound 1-4 to block transcription. Cells were collected at different time points after treatment, intracellular RNA was extracted, and qRT-PCR was used to detect changes in HBV mRNA. The results showed that the half-life of the compound 1-4 group was basically the same as that of the DMSO control group, that is, compound 1-4 did not affect the degradation rate of HBV RNA ( Figure 5 C), suggesting that compounds 1-4 affect HBsAg by affecting the production of HBV RNA.
[0066] The HBsAg extracellular / intracellular ratio is an important biological characteristic of HBV and can reflect the secretion rate of HBsAg. In order to study whether compounds 1-4 would affect the secretion rate of HBsAg, we tested the HBsAg extracellular / intracellular ratio after the action of compounds 1-4 in different cell lines, as well as the HiBiT extracellular / intracellular ratio, which can characterize HBsAg and has a wider detection linear range. The results showed that compounds 1-4 had a slight effect on HBsAg secretion in the HepG2 cell model ( Figure 5 D) had no significant effect on HBsAg secretion in HepG2.2.15 cell model, HepAD38 cell model and AML12 cell model ( Figure 5 E, 5F).
[0067] In summary, compound 1-4 is a new potential antiviral drug that inhibits HBsAg by inhibiting HBV transcription.
Claims
1. Use of the compound or a pharmaceutically acceptable salt thereof in any of the following: (1) Application in the preparation of reagents for inhibiting HBV transcription; (2) Application in the preparation of HBV inhibitors; (3) Application in the preparation of hepatitis B surface antigen inhibitors; (4) Use in the preparation of drugs for treating hepatitis B virus infectious diseases or symptoms; (5) Application in the preparation of drugs against hepatitis B virus; The compound is selected from any one of the following compounds:
2. The use according to claim 1, Features: The compound is a compound having a chemical structural formula shown in formula (1-4).
3. The use according to claim 1, Features: The medicament further includes a pharmaceutically acceptable carrier.
4. A product for inhibiting HBV transcription or inhibiting HBV or inhibiting hepatitis B surface antigen, Features: Containing at least one of the compounds represented by Formula I, Formula (1-1), Formula (1-2), Formula (1-4), and Formula (1-6) in Claim 1 as an active ingredient, or a pharmaceutically acceptable salt of the compound.
5. The product according to claim 4, Features: The product is a medicine, which also contains a pharmaceutically acceptable carrier.
6. A pharmaceutical composition for treating a disease or condition caused by hepatitis B virus or for resisting hepatitis B virus, Features: Containing as an active ingredient at least one of the compounds represented by Formula I, Formula (1-1), Formula (1-2), Formula (1-4), and Formula (1-6) in Claim 1 or a pharmaceutically acceptable salt of the compound, and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition according to claim 6, Features: The active ingredient exerts its efficacy by inhibiting hepatitis B surface antigen.
8. The pharmaceutical composition according to claim 7, Features: The compound is a compound with a chemical structural formula shown in formula (1-4), which inhibits hepatitis B surface antigen by inhibiting HBV transcription.
9. The pharmaceutical composition according to claim 8, Features: The compound with the chemical structure shown in formula (1-4) affects the hepatitis B surface antigen by affecting the production of HBV RNA.
10. The pharmaceutical composition according to claim 9, Features: The product dosage form of the pharmaceutical composition is capsule, tablet, pill, granule, oral solution preparation, microcapsule preparation or injection.
Citation Information
Patent Citations
Compound for inhibiting hepatitis B surface antigen and application thereof
CN117503772A
Cited By
Compound for inhibiting hepatitis B surface antigen and application thereof
CN117503772A
Compounds inhibiting hepatitis b surface antigen and uses thereof
CN117503772B
Application of host factor TMEM40 in regulating and controlling hepatitis B virus antigen expression and resisting HBV
CN121313797A
